FDA Approved Biologics and Pending Applications
Inter Partes Review Proceedings
DUPIXENTIPR2017-01129IPR2017-01879IPR2017-01884EYLEAIPR2020-01317IPR2020-01318IPR2020-01320IPR2021-00402IPR2021-00816IPR2021-00880IPR2021-00881IPR2022-00257IPR2022-00258IPR2022-00298IPR2022-00301IPR2022-01225IPR2022-01226IPR2022-01524IPR2023-00099IPR2023-00442IPR2023-00462IPR2023-00532IPR2023-00533IPR2023-00566IPR2023-00620IPR2023-00739IPR2023-00884IPR2023-01312IPR2024-00201IPR2024-00260IPR2024-00298IPR2025-00176IPR2025-00233PGR2021-00035PGR2021-00117GENENTECH CABILLYIPR2015-01624EYLEA / AHZANTIVEIPR2025-00233EYLEA / CT-P42IPR2022-00257IPR2022-00258IPR2023-00462IPR2023-00532IPR2023-00533IPR2023-00620IPR2024-00260PGR2021-00117EYLEA / LUCENTISIPR2020-01317IPR2020-01318IPR2020-01320IPR2021-00816EYLEA / OPUVIZIPR2023-00442IPR2023-00566IPR2023-00739IPR2023-00884IPR2023-01312IPR2025-00176EYLEA / YESAFILIIPR2021-00880IPR2021-00881IPR2022-01225IPR2022-01226IPR2023-00099IPR2024-00201IPR2024-00298
U.S. Patent Litigations
DUPIXENT1:17-cv-10465 (D. Mass.)2:17-cv-02613 (C.D. Cal.)ZALTRAP1:18-cv-02434 (S.D.N.Y.)7:11-cv-09463 (S.D.N.Y.)EYLEA / AHZANTIVE1:23-cv-00097 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)EYLEA / CT-P421:23-cv-00089 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)1:24-cv-00053 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)EYLEA / ENZEEVU1:24-cv-00085 (N.D.W. Va.) (transferred from 2:24-cv-08760 (D.N.J.)) / MDL 1:24-md-03103 (N.D.W. Va.)EYLEA / LUCENTIS1:18-cv-02434 (S.D.N.Y.)1:20-cv-00690 (N.D.N.Y.)EYLEA / LUCENTIS / ZALTRAP1:18-cv-02434 (S.D.N.Y.)EYLEA / OPUVIZ1:23-cv-00094 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)1:23-cv-00106 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)EYLEA / PAVBLU1:24-cv-00039 (N.D.W. Va.) (transferred from 1:24-cv-00264 (C.D. Cal.)) / MDL 1:24-md-03103 (N.D.W. Va.)EYLEA / YESAFILI1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)PRALUENT / GENENTECH CABILLY2:15-cv-05685 (C.D. Cal.)PRALUENT / REPATHA1:14-cv-01317 (D. Del.)1:14-cv-01349 (D. Del.)1:14-cv-01393 (D. Del.)1:14-cv-01414 (D. Del.)
